Efficacy of biologic therapy in patients with severe occupational and work-related asthma

Severe asthma is characterized by significant prevalence and unfavorable outcomes. Biological therapy with monoclonal antibodies significantly improves the prognosis of T2-phenotype of severe asthma. Features of allergic occupational asthma associated with the properties of industrial allergens determine the need to study its response to biological therapy. The aim of the study was to determine the effectiveness of biological therapy with monoclonal antibodies in patients with occupational or work-related asthma in real clinical practice. Methods. A prospective observational study was conducted involving patients with severe occupational and work-related asthma (n = 49) receiving therapy with monoclonal antibodies (omalizumab (n = 19), reslizumab (n = 3), mepolizumab (n = 8), dupilumab (n = 9), benralizumab (n = 11)). The diagnosis of asthma was confirmed by a positive bronchodilator test. The occupational and work-related nature of the disease was identified by allergy tests or return-to-work test. The primary endpoints were symptom control (ACQ-5 < 0.75) and asthma exacerbations. Statistical analysis was performed using descriptive statistics methods (median and interquartile range, proportions), Mann – Whitney test or χ2 criterion for comparison of independent groups, Wilcoxon test or McNemar criterion for interrelated groups. Cox proportional hazards method was used to search for factors associated with endpoints, Kaplan–Meier method was used for survival analysis. Results. The observation period was 12 – 60 months. Asthma control was achieved in 39 (79.6 %) patients. The following factors were associated with achieving asthma control (relative risk; 95% confidence interval): sensitization to a low-molecular allergen (2.30; 1.84–3.46), a decrease in the forced expiratory volume in 1 second (FEV1) after exercise (0.89; 0.50 – 0.97), and blood eosinophilia (1.02; 1.01 – 1.05). Exacerbations were noted in 49 (100%) subjects before treatment and in 16 (32.7%) during therapy (p = 0.0001). Sensitization to a low-molecular allergen and high baseline blood eosinophilia reduced the likelihood of exacerbations during treatment (0.27; 0.15 – 0.86 and 0.96; 0.92 – 0.99). In the Kaplan–Meier analysis, the probability of symptom control was 90.3% in patients with low-molecular-weight allergen-induced asthma and 61.1% in patients with high-molecular-weight allergens. The survival rate without exacerbations was 72.3% and 37.7%, respectively (p < 0.05). FEV1 increased, and blood eosinophilia decreased. Conclusion. In patients with occupational and work-related asthma, biological therapy prevents exacerbations, increases the probability of symptom control, and improves lung function, primarily in asthma caused by low-molecular-weight allergens.

1. Chen C.Y., Wu K.H., Guo B.C. et al. Personalized medicine in severe asthma: from biomarkers to biologics. Int. J. Mol. Sci. 2023; 25 (1): 182. DOI: 10.3390/ijms25010182.

2. Roche N., Garcia G., de Larrard A. et al. Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France. BMJ Open. 2022; 12 (8): e060160. DOI: 10.1136/bmjopen-2021-060160.

3. Kimura Y., Suzukawa M., Jo T. et al. Epidemiology of patients with severe asthma in Japan: a nationwide descriptive study. ERJ Open Res. 2024; 10 (4): 00122-2024. DOI: 10.1183/23120541.00122-2024.

4. Wang E., Wechsler M.E., Tran T.N. et al. Characterization of severe asthma worldwide: data from the international severe asthma registry. Chest. 2020; 157 (4): 790–804. DOI: 10.1016/j.chest.2019.10.053.

5. Sousa A.W., Barros Cabral A.L., Arruda Martins M., Carvalho C.R.F. Risk factors for fixed airflow obstruction in children and adolescents with asthma: 4-year follow-up. Pediatr. Pulmonol. 2020; 55 (3): 591–598. DOI: 10.1002/ppul.24625.

6. Belevskiy A.S., Nenasheva N.M., Kravchenko N.Yu. et al. [Data from the Russian Severe Asthma Registry (RSAR)]. Terapevticheskiy arkhiv. 2022; 94 (7): 865–871. DOI: 10.26442/00403660.2022.07.201713 (in Russian).

7. Korn S., Schmidt O., Timmermann H. et al. Real-world characteristics of patients with severe asthma prior to starting Dupilumab: the ProVENT study. Respiration. 2024;103 (1): 10–21. DOI: 10.1159/000535390.

8. Nagarajan S., Rosenbaum J., Joks R. The relationship between allergic rhinitis, asthma, and cardiovascular disease in the National Health Interview Surveys (NHIS), 1999–2018. J. Allergy Clin. Immunol. Pract. 2024; 12 (6): 1509–1519.e4. DOI: 10.1016/j.jaip.2024.02.001.

9. Ekström M., Nwaru B.I., Hasvold P. et al. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019; 74 (11): 2181–2190. DOI: 10.1111/all.13874.

10. Larsson K., Ställberg B., Lisspers K. et al. Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). Respir. Res. 2018; 19 (1): 12. DOI: 10.1186/s12931-018-0719-x.

11. Kankaanranta H., Viinanen A., Ilmarinen P. et al. Comorbidity burden in severe and nonsevere asthma: a nationwide observational study (FINASTHMA). J. Allergy Clin. Immunol. Pract. 2024; 12 (1): 135–145.e9. DOI: 10.1016/j.jaip.2023.09.034.

12. Arkhipov V.V., Aisanov Z.R., Avdeev S.N. [Effectiveness of inhaled corticosteroids and long-acting β-agonists combinations in real clinical practice: results of a multicenter cross-sectional study in Russian patients with asthma]. Pul'monologiya. 2021; 31 (5): 613–626. DOI: 10.18093/0869-0189-2021-31-5-613-626 (in Russian).

13. Romero-Mesones C., Cruz M.J., Alobid I. et al. Disposition of work-related asthma in a Spanish asthma cohort: comparison of asthma severity between employed and retired workers. J. Allergy Clin. Immunol. Pract. 2023; 11 (11): 3407–3413.e1. DOI: 10.1016/j.jaip.2023.06.040.

14. Vandenplas O., Godet J., Hurdubaea L. et al. Severe occupational asthma: insights from a multicenter European cohort. J. Allergy Clin. Immunol. Pract. 2019; 7 (7): 2309–2318.e4. DOI: 10.1016/j.jaip.2019.03.017.

15. Mason P., Biasioli M., Liviero F. Endotypes of occupational asthma. Curr. Opin. Allergy Clin. Immunol. 2024; 24 (2): 58–63. DOI: 10.1097/ACI.0000000000000969.

16. Chan R., Stewart K., Misirovs R., Lipworth B.J. Targeting downstream type 2 cytokines or upstream epithelial alarmins for severe asthma. J. Allergy Clin. Immunol. Pract. 2022; 10 (6): 1497–1505. DOI: 10.1016/j.jaip.2022.01.040.

17. Ando K., Fukuda Y., Tanaka A., Sagara H. Comparative efficacy and safety of Tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis. Cells. 2022; 11 (5): 819. DOI: 10.3390/cells11050819.

18. Kim H., Kim M.G., Kim S.R. et al. Comparative efficacy of biologics for patients with inadequately controlled asthma: a network meta-analysis. World Allergy Organ. J. 2024; 17 (7): 100934. DOI: 10.1016/j.waojou.2024.100934.

19. Vasilyeva O.S., Kuzmina L.P., Kolyaskina M.M. [Occupational bronchial asthma caused by exposure to polyvinyl chloride: phenotypes of the disease]. Meditsina truda i promyshlennaya ekologiya. 2018; (12): 14–18. DOI: 10.31089/1026-9428-2018-12-14-18 (in Russian).

20. Lau A., Tarlo S.M. Update on the management of occupational asthma and work-exacerbated asthma. Allergy Asthma Immunol. Res. 2019; 11 (2): 188–200. DOI: 10.4168/aair.2019.11.2.188.

21. Vandenplas O., Godet J., Hurdubaea L. et al. Are high- and low-molecular-weight sensitizing agents associated with different clinical phenotypes of occupational asthma? Allergy. 2019; 74 (2): 261–272. DOI: 10.1111/all.13542.

22. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. [Federal guidelines on diagnosis and treatment of bronchial asthma]. Pul'monologiya. 2022; 32 (3): 393–447. DOI: 10.18093/0869-0189-2022-32-3-393-447 (in Russian).

23. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention Reports. 2025. Available at: https://ginasthma.org/reports/

24. Bourdin A., Brusselle G., Couillard S. et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. J. Allergy Clin. Immunol. Pract. 2024; 12 (4): 809–823. DOI: 10.1016/j.jaip.2024.01.023.

25. Milger K., Suhling H., Skowasch D. et al. Response to biologics and clinical remission in the adult German asthma net severe asthma registry cohort. J. Allergy Clin. Immunol. Pract. 2023; 11 (9): 2701–2712.e2. DOI: 10.1016/j.jaip.2023.05.047.

26. Sasano H., Harada N., Harada S. et al. Pretreatment circulating MAIT cells, neutrophils, and periostin predicted the real-world response after 1-year mepolizumab treatment in asthmatics. Allergol. Int. 2024; 73 (1): 94–106. DOI: 10.1016/j.alit.2023.06.001.

27. Busse W.W., Chupp G., Corbridge T. et al. Targeting asthma remission as the next therapeutic step toward improving disease control. J. Allergy Clin. Immunol. Pract. 2024; 12 (4): 894–903. DOI: 10.1016/j.jaip.2024.01.044.

28. Peredelskaya M.Yu., Nenasheva N.M., Sebekina O.V., Belevskiy A.S. [Asthma clinical remission]. Prakticheskaya pul'monologiya. 2023; (1): 3–10. DOI: 10.24412/2409-6636-2023-12854 (in Russian).

29. Sposato B., Bianchi F., Ricci A., Scalese M. Clinical asthma remission obtained with biologics in real life: patients' prevalence and characteristics. J. Pers. Med. 2023; 13 (6): 1020. DOI: 10.3390/jpm13061020.

30. Hansen S., Baastrup Søndergaard M., von Bülow A. et al. Clinical response and remission in patients with severe asthma treated with biologic therapies. Chest. 2024; 165 (2): 253–266. DOI: 10.1016/j.chest.2023.10.046.

31. Pavord I., Gardiner F., Heaney L.G. et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front. Immunol. 2023; 14: 1150162. DOI: 10.3389/fimmu.2023.1150162.